Dr. Wanxing Cui is the director of the Cell Therapy Manufacturing Facility at Medstar Georgetown University Hospital. Dr. Cui received medical training in Shenyang, China, and practiced general surgery as a resident surgeon for three years. He earned his Ph.D. degree at Kyoto University, Japan, in 2001 with research on bioartificial pancreas development. Since then, Dr. Cui has been working on pancreatic islet transplantation at Emory University, the University of Alabama at Birmingham, and Georgetown University for more than twenty years. His research covers a wide spectrum from basic studies with rodent islets and preclinical studies with non-human primate islets to clinical trials with human islets, using a multidisciplinary translational approach. Dr. Cui has published 58 scientific papers and possesses five islet and bioengineering-related patents currently. Dr. Cui has been a standing International Pancreas and Islet Transplant Association (IPITA) member for more than 20 years. At present, Dr. Cui is an active committee member of the Association for the Advanced of Blood and Biotherapies (AABB) cellular therapies section.
